PHAR 7633 Chapter 20 Non Compartmental Analysis

Similar documents
1. If the MTC is 100 ng/ml and the MEC is 0.12 ng/ml, which of the following dosing regimen(s) are in the therapeutic window?

BASIC PHARMACOKINETICS

PHA Final Exam Fall 2006

Nontraditional PharmD Program PRDO 7700 Pharmacokinetics Review Self-Assessment

PHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

General Principles of Pharmacology and Toxicology

PHAR 7632 Chapter 16

Basic Pharmacokinetic Principles Stephen P. Roush, Pharm.D. Clinical Coordinator, Department of Pharmacy

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

PHA 5127 FINAL EXAM FALL On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Multiple IV Bolus Dose Administration

Osnove farmakokinetike. Aleš Mrhar. Prirejeno po. A First Course in Pharmacokinetics and Biopharmaceutics by David Bourne,

Flecainide pharmacokinetics in healthy volunteers: the influence of urinary ph

BIOPHARMACEUTICS and CLINICAL PHARMACY

PHA Second Exam Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

PHA Spring First Exam. 8 Aminoglycosides (5 points)

Biomath M263 Clinical Pharmacology

Basic Pharmacokinetics and Pharmacodynamics: An Integrated Textbook with Computer Simulations

PHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

PHARMACOKINETICS SMALL GROUP II:

PHARMACOKINETICS SMALL GROUP I:

PHARMACOKINETICS OF DRUG ABSORPTION

Pharmacokinetics Overview

Name: UFID: PHA Exam 2. Spring 2013

PHA 4120 Second Exam Key Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Biopharmaceutics Lecture-11 & 12. Pharmacokinetics of oral absorption

PHA Final Exam Fall 2001

Nonlinear Pharmacokinetics

PHA5128 Dose Optimization II Case Study I Spring 2013

Pharmacokinetics of ibuprofen in man. I. Free and total

Clinical Pharmacology. Pharmacodynamics the next step. Nick Holford Dept Pharmacology & Clinical Pharmacology University of Auckland, New Zealand

Thus, we can group the entire loading dose together as though it was given as a single dose, all administered when the first dose was given.

Pharmacokinetic Calculations

Carbamazepine has a clearance of L/h/kg for monotherapy. For immediate release carbamazepine, the oral bioavailbility is 0.8

Pharmacokinetics Applied to the Treatment of Asthma

Basic Concepts of TDM

One-Compartment Open Model: Intravenous Bolus Administration:

Lippincott Questions Pharmacology

In vitro and in vivo deconvolution assessment of drug release kinetics from oxprenolol Oros preparations

Determination of bioavailability

PHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

LD = (Vd x Cp)/F (Vd x Cp)/F MD = (Css x CL x T)/F DR = (Css x (Vm-DR))/Km Css = (F x D)/(CL x T) (Km x DR)/(Vm DR)

Pharmacodynamic principles and the time course of immediate drug effects

CLINICAL PHARMACOKINETICS INDEPENDENT LEARNING MODULE

TDM. Measurement techniques used to determine cyclosporine level include:

Guideline for Bioequivalence Studies of Generic Products

DEVELOPMENT OF IN VITRO-IN VIVO CORRELATION FOR ENCAPSULATED METOPROLOL TARTRATE

Principles of Toxicokinetics/Toxicodynanics

. Although there is a little

C OBJECTIVES. Basic Pharmacokinetics LESSON. After completing Lesson 2, you should be able to:

Pharmacokinetics of drug infusions

NONLINEAR PHARMACOKINETICS: INTRODUCTION

Case Study 2 Answers Spring 2006

Understand the physiological determinants of extent and rate of absorption

Clinical Trials A Practical Guide to Design, Analysis, and Reporting

Chapter 5 Herb-Drug Interactions: Glibenclamide

Take-Home Exam Distributed: October 16, 2013, at 1:30 p.m. Due: October 21, 2013, at 10:00 a.m.

Vancomycin Pharmacokinetics in Normal and Morbidly Obese Subjects

The general Concepts of Pharmacokinetics

Tutorial. & In case studies 1 and 2, we explore intravenous iv. & Then, we move on to extravascular dosing in case

Bioequivalence of Inhaled Corticosteroids. -with emphasis on Pharmacokinetic Tools.

Introduction to. Pharmacokinetics. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D

Public Assessment Report. EU worksharing project paediatric data. Valcyte. Valganciclovir

Noncompartmental Analysis (NCA) in PK, PK-based Design

Pharmacokinetics One- compartment Open Model Lec:2

PHA 5128 Spring 2009 First Exam (Version B)

Intrasubject Variation in Elimination Half-Lives of Drugs Which Are Appreciably Metabolized

PHA 5128 Final Exam Spring 2004 Version A. On my honor, I have neither given nor received unauthorized aid in doing this assignment.

A Bioequivalence Study of an Albendazole Oral Suspension Produced in Iran and a Reference Product in Sheep

Comparing Methods for Once Daily Tobramycin Exposure Predictions in Children with Cystic Fibrosis

Determination of free interstitial concentrations of piperacillin tazobactam combinations by microdialysis

ADAM, a hands-on patient simulator for teaching principles of drug disposition and compartmental pharmacokinetics

Pharmacokinetic Study of [Di (4-amino N-acetyl) phenoxy]methyl ketone as Compared to Paracetamol

Use of PBPK in simulating drug concentrations in pediatric populations: Case studies of Midazolam and Gabapentin

General Principles of Pharmacology and Toxicology

Gastrointestinal Transit and Drug Absorption

Bioavailability and Related Pharmacokinetics in Man of Orally Administered L-5-Hydroxytryptophan in Steady State

PHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Volume 1(3) May-June 2013 Page 351

PHARMACOKINETICS OF SULFAMETHAZINE IN BUFFALOES

These results are supplied for informational purposes only.

PHA5128 Dose Optimization II Case Study 3 Spring 2013

Noncompartmental Analysis (NCA) in PK, PK-based Design

TDM of Digoxin. Use of Digoxin Serum Concentrations to Alter Dosages

Modeling and Simulation to Support Development and Approval of Complex Products

Pharmacokinetics PCTH 325. Dr. Shabbits September 12, C t = C 0 e -kt. Learning Objectives

Pharmacokinetics of Rifampicin in African Children Evaluation of the new WHO dosing guidelines

Package NonCompart. August 16, 2017

Pharmacokinetics and allometric scaling of levormeloxifene, a selective oestrogen receptor modulator

Mechanisms of Drug Action

Redacted for privacy

NIH Public Access Author Manuscript Am J Nephrol. Author manuscript; available in PMC 2015 January 22.

Pharmacogenetics and Pharmacokinetics

Applied Biopharmaceutics & Pharmacokinetics Sixth Edition

PHA 5128 CASE STUDY 5 (Digoxin, Cyclosporine, and Methotrexate) Spring 2007

7. SUMMARY, CONCLUSION AND RECOMMENDATIONS

PART 1. Pharmacology

The comparative effects of verapamil and a new dihydropyridine calcium channel blocker on digoxin pharmacokinetics

Bioavailability and Pharmacokinetics of Isradipine after Oral and Intravenous Administration: Half-Life Shorter than Expected?

Transcription:

Student Objectives for this Chapter PHAR 7633 Chapter 20 Non Compartmental Analysis To understand and use the non compartmental approach to parameter estimation be able to define, use, and calculate the parameters: AUMC (area under the first moment curve) MRT (mean residence time) MAT (mean absorption time) MDT (mean dissolution time) Non Compartmental Analysis Non compartmental methods can be used to determine certain pharmacokinetic parameters without deciding on a particular compartmental model. The basic calculations are based on the area under the plasma concentration versus times curve (zero moment) and the first moment curve (AUMC). The AUC can be calculated as before using the trapezoidal rule. The first moment is calculated as concentration times time (Cp t). The AUMC is the area under the concentration times time versus time curve. Maybe best covered with an example. Consider a drug given both by IV and oral administration. Both the AUC and AUMC were calculated using the trapezoidal rule without making any assumption concerning the number of compartments. The final segment of the AUC curve is calculated as Cp(last)/k', where k' is the last exponential term (the slowest) calculated from the Cp versus time graph. The last segment for the AUMC curve is: Equation 20.1.1 Equation of the last segment AUMC Page 1 of 8

Time (hr) Cp (mg/l) Cp t (mg.hr/l) AUC (mg.hr/l) AUMC (mg.hr 2 /L) 0 8 0 0 0 1 7.09 7.09 7.55 3.55 2 6.29 12.58 14.24 13.39 3 5.58 16.74 20.18 28.05 4 4.95 19.80 25.45 46.32 6 3.89 23.34 34.29 89.46 9 2.71 24.39 44.19 161.06 12 1.89 22.68 51.09 231.67 18 0.92 16.56 59.52 349.39 24 0.44 10.56 63.60 430.75 67.27 549.31 Table 20.1.1 Typical Cp versus Time Data after 100 mg IV Bolus Administration These data, Cp versus time and Cp x time versus time, can be plotted on linear graph. Page 2 of 8

Figure 20.1.1 Plot of Cp versus Time (IV) and various parameters can be calculated as: Figure 20.1.2 Plot of Cp x Time versus Time (IV) Equation 20.1.2 Equation for Mean Residence Time (MRT) Equation 20.1.3 Equation for Apparent Elimination Rate constant (kel') Page 3 of 8

Equation 20.1.4 Equation for Total Body Clearance (TBC) Equation 20.1.5 Equation for Apparent Volume of Distribution, Steady State (V ss ) From the AUC and AUMC values we can calculate the mean residence time, MRT. This is the average time that the drug stays in the body (or plasma as measured here). It can be related to the average elimination rate constant as 1/MRT. The values from the above data are MRT = 549.31/67.27 = 8.17 hr and kel' = 1/8.17 = 0.12 hr -1 Remember we can also calculate the clearance, CL = Dose/AUC = 100/67.27 = 1.49 L.hr -1 Finally a steady state volume can be calculated as V ss = CL MRT = 1.49 x 8.17 = 12.14 L Page 4 of 8

Oral data can be analyzed by these methods as well. Time (hr) Cp (mg/l) Cp t (mg.hr/l) AUC (mg.hr/l) AUMC (mg.hr 2 /L) 0 0 0 0 0 1 12.18 12.2 6.09 6.09 2 14.12 28.24 19.24 26.30 3 13.43 40.29 33.02 60.57 4 12.16 48.64 45.82 105.04 6 9.64 57.84 67.62 211.52 9 6.73 60.57 92.18 389.14 12 4.69 56.24 109.31 564.42 18 2.28 41.22 130.25 856.92 24 1.11 26.64 140.45 1060.50 149.70 1359.58 Table 20.1.2 Typical Cp versus Time Data after 250 mg Oral Administration These data, Cp versus time and Cp x time versus time, can be plotted on linear graph. Figure 20.1.3 Plot of Cp versus Time (PO) Page 5 of 8

Figure 20.1.4 Plot of Cp x Time versus Time (PO) and additional parameters can be calculated (NOTE: We don't calculate Clearance or V ss using oral data). Equation 20.1.6 Equation for Mean Absorption Time (MAT) Equation 20.1.7 Equation for Apparent Absorption Rate Constant (ka') Equation 20.1.8 Equation for Oral Bioavailability (F) The data were calculated after a 250 mg oral dose of the same drug. From these data a MRT was calculated as MRT = AUMC/AUC = 1361/149.8 = 9.08 hr We can subtract from this MRT(PO) the MRT(IV) to get an idea of the absorption process, the mean absorption time (MAT). That is MAT = MRT(PO) - MRT(IV) = 9.08-8.17 = 0.92 hr From this we can calculate an average absorption rate constant ka' = 1/MAT = 1/0.92 = 1.09 hr -1 Of course we can calculate the bioavailability of the oral dosage form using the dose adjusted AUC ratio. Thus F = (149.70/67.27) x (100/250) = 0.89 Page 6 of 8

Another Example using Data from Bevill et al. 1977 Pharmacokinetics of Sulfamethazine in Cattle following IV and Three Oral Dosage Forms Dosage Forms IV Bolus 107 mg/kg Oral Solution 107 mg/kg Oral Rapid Release Tablet 105 mg/kg Oral Sustained Release Tablet 249 mg/kg Figure 20.1.5 The Average Data from Each Dosage Form AUC AUMC MRT (hr) MAT (hr) MDT (hr) IV 437 6393 14.6 - - Solution 431 9454 21.9 7.3 - Tablet 450 11303 25.1 10.5 3.2 Slow Tablet 765 45484 59.5 44.9 37.6 Table 20.1.6 Non Compartmental Analysis Results Rate Constant (hr -1 ) Non Linear Regression Analysis Non Compartmental Analysis kel' 0.077 0.068 ka' 0.11 0.14 kd' (fast) 0.41 0.31 kd' (slow) 0.026 0.027 Table 20.1.7 Comparison with Non Linear Regression Analysis (SAAM) Page 7 of 8

Non compartmental analysis: kel' = 1/MRT ka' = 1/MAT kd' = 1/MDT where MDT is the mean dissolution time Want more practice with this type of problem! References Bevill, R.F., Dittert, L.W. and Bourne, D.W.A. 1977 Pharmacokinetics of Sulfamethazine in Cattle following IV and Three Oral Dosage Forms, J. Pharm. Sci., 66, 619-23 This page (http://www.boomer.org/c/p4/c20/c2001.html) was last modified: Wednesday 26 May 2010 at 09:00 AM Material on this website should be used for Educational or Self-Study Purposes Only Copyright 2001-2014 David W. A. Bourne (david@boomer.org) Page 8 of 8